{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', '7.', 'SELECTION AND WITHDRAWAL OF SUBJECTS', 'The inclusion and exclusion criteria for participation in PART 1 and PART 2 are provided', 'below. All screening assessments must be completed during the SPIMM-301 Screening Period,', 'but may be performed on different days. Screening assessments should not be repeated, and', \"subjects cannot be re-screened without the Sponsor's approval. If a subject is re-screened, they\", 'will maintain their original screening number. Subjects may only be enrolled into the trial one', 'time.', 'Prospective approval of protocol deviations to enrollment criteria, also known as protocol', 'waivers or exemptions, are not permitted.', 'While there is no screening period for PART 2, subjects continuing into PART 2 must meet the', 'PART 2 Continuation Criteria. Subjects who decide not to continue in the PART 2 at the PART', '1 Week 24 Visit are not eligible to participate in PART 2.', '7.1.', 'SPIMM-301 Eligibility', '7.1.1.', 'Subject Inclusion Criteria', 'A subject must meet all of the following Inclusion Criteria at the Baseline Visit to be eligible for', 'inclusion in the SPIMM-301 trial:', '1. Willing and able to provide a signed informed consent form (ICF) prior to participation in', 'any trial-related procedures.', '2. Agrees and is able to adhere to the trial requirements for the length of the trial, including', 'the use of the elamipretide delivery system.', '3. Subject is >16 and 80 years of age. In Germany, subjects must be >18 years of age.', '4. Enrolled (signed ICF) in SPIMM-300 or have prior approval from the Sponsor to enroll', 'without SPIMM-300 participation.', '5. Diagnosed with PMM in the opinion of the Investigator, consisting of:', 'a.', 'Molecular genetic abnormality of the mitochondrial respiratory chain, and', 'b. Subject reported symptoms (i.e., exercise intolerance, fatigue, muscle weakness)', 'or physical examination findings of myopathy that are the predominant symptoms', \"of the subject's mitochondrial respiratory chain disorder.\", \"6. The subject's molecular genetic abnormality is consistent with PMM as confirmed by the\", 'Adjudication Committee.', '7.', 'Women of childbearing potential must agree to use 1 of the following methods of birth', 'control from the date they sign the ICF until 28 days after the last dose of IMP:', 'a. Abstinence, when it is in line with the preferred and usual lifestyle of the subject.', 'Subject agrees to use a highly effective method of contraception should they', 'become sexually active.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '52']['SPIMM-301 Version 4.0', '15 June 2018', 'b. Relationships with male partners who have been surgically sterilized by', 'vasectomy (the vasectomy procedure must have been conducted at least 60 days', 'prior to the Screening Visit).', 'c. Barrier method (e.g., condom or occlusive cap) with spermicidal', 'foam/gel/film/cream AND either hormonal contraception (oral, implanted, or', 'injectable) or an intrauterine device or system.', 'Note: Non-childbearing potential is defined as surgical sterilization (e.g., bilateral', 'oophorectomy, hysterectomy, or tubal ligation) or postmenopausal (defined as', 'permanent cessation of menstruation for at least 12 consecutive months prior to the', 'Screening Visit).', '8. Male subjects with female partners of child-bearing potential must be willing to use a', 'highly effective method of contraception from the date they sign the ICF until 28 days', 'after the last dose of IMP.', '7.1.2.', 'SPIMM-301 Exclusion Criteria', 'A subject CANNOT meet any of the following Exclusion Criteria at the SPIMM-301 Baseline', 'Visit to be eligible for inclusion in the trial:', '1. Subject has myopathic signs and/or symptoms due to a neuropathic process (i.e.', 'cerebellar dysfunctions and peripheral neuropathies) or a gait problem that would', 'interfere with the 6MWT, in the opinion of the Investigator.', '2. Female subjects who are pregnant, planning to become pregnant, or', 'breastfeeding/lactating.', '3. Walks < 100 meters or > 450 meters during the 6MWT at either the Screening Visit OR', 'Baseline Visit.', '4. At the Baseline Visit, the estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73', 'm\u00b2, using the Screening Visit value with the Modification of Diet in Renal Disease', '(MDRD) Study equation.', '5. Subject has undergone an in-patient hospitalization within the 30 days prior to the', 'Baseline Visit or has a planned hospitalization or a surgical procedure during the trial.', '6. Subject has clinically significant respiratory disease and/or cardiac disease (medical', 'history or current clinical findings), in the opinion of the Investigator, or prior', 'interventional cardiac procedure (e.g., cardiac catheterization, angioplasty/percutaneous', 'coronary intervention, balloon valvuloplasty, etc.) within 3 months of the Baseline Visit.', '7. Subject has a pacemaker, implantable cardioverter-defibrillator, or cardiac', 'resynchronization therapy device OR QTc elongation (using the correction factor utilized', 'at the clinical site) defined as a QTc >450 msec in male subjects and >480 msec in', 'female subjects.', 'Note: At the initial electrocardiogram (ECG), if QTc exceeds these parameters, the ECG', 'may be repeated 2 more times (during the same visit), and the average of the 3 QTc', \"values used to determine the subject's eligibility.\", 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '53']\n\n###\n\n", "completion": "END"}